<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587496</url>
  </required_header>
  <id_info>
    <org_study_id>6475</org_study_id>
    <secondary_id>EY002672</secondary_id>
    <nct_id>NCT00587496</nct_id>
  </id_info>
  <brief_title>30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers</brief_title>
  <official_title>A 30-Day Double-Masked Study to Determine the Effect of Oral Valacyclovir or Oral Valacyclovir Plus Aspirin on the Shedding of Herpes Simplex Virus DNA in the Tears and Saliva of Volunteers Without Clinical Signs of Ocular Herpetic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Eye Institute (NEI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral Valtrex alone or in combination with
      aspirin will reduce the shedding of herpes simplex virus DNA in the tears and saliva from
      volunteers with no evidence of ocular herpes infection. The secretion of virus into the tears
      and saliva might make people more susceptible to virus infection in the future if their
      immune system becomes deficient. The study will also try to determine if there is a
      correlation between shedding of viral DNA and herpes virus antibodies in serum and to
      determine if subjects are carriers of a special form of a gene in their blood cells, the
      presence of which may suggest the possibility of an increased susceptability to herpes and to
      Alzheimer's disease and heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Published studies have shown that treatment with oral acyclovir reduced clinical recurrences
      of ocular herpetic keratitis by about 40-50 %8, and treatment with valacyclovir, a more
      soluble prodrug of acyclovir, reduced the risk of transmission of genital herpes9, 10, 11.
      For this study, we will use the dose of valacyclovir that was shown effective in reducing the
      risk of transmission of HSV-2.9 The dose of 325 mg aspirin three times a day was chosen based
      on our experience with mice and other laboratory animals12. If it is effective and well
      tolerated at this dose, in future studies we will attempt to use lower doses and determine if
      they too may be effective.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">July 2008</completion_date>
  <primary_completion_date type="Anticipated">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of DNA shedding above the positive detection threshold</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo, 6 capsules per day for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Valtrex one capsule per day plus 5 capsules of placebo per day for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Valtrex capsule one per day, Acetylsalicylic acid (aspirin) 325 mg capsules three per day, plus 2 placebo capsules per day for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir hydrochloride</intervention_name>
    <description>500 mg capsule, one per day for 30 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>lactose placebo capsule, six per day for 30 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir plus aspirin</intervention_name>
    <description>500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  either sex

          -  any race

          -  over age of 21 years

        Exclusion Criteria:

          -  have active ocular herpetic lesion

          -  had ocular herpetic lesion in past 30 days

          -  taking systemic or oral antiviral drugs

          -  have taken antiviral drugs in the past 30 days

          -  taking aspirin or NSAIDs

          -  have dry eyes

          -  have hypersensitivity to acyclovir or valacyclovir

          -  have hypersensitivity of contraindication to use of aspirin

          -  have bleeding disorder

          -  have GI ulcer

          -  have kidney impairment

          -  are pregnant or nursing

          -  have participated in a clinical trial in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert E Kaufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSU Eye Center, LSU Health Sciences Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily D Varnell, BS</last_name>
    <phone>504 568-2254</phone>
    <email>evarne@lsuhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Cooper, BS</last_name>
    <phone>504 568-2815</phone>
    <email>rcoope@lsuhsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LSU Eye Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Herbert E Kaufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci. 2005 Jan;46(1):241-7.</citation>
    <PMID>15623779</PMID>
  </reference>
  <reference>
    <citation>Lindgren KM, Douglas RG Jr, Couch RB. Significance of Herpesvirus hominis in respiratory secretions of man. N Engl J Med. 1968 Mar 7;278(10):517-23.</citation>
    <PMID>4295319</PMID>
  </reference>
  <reference>
    <citation>Douglas RG Jr, Couch RB. A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans. J Immunol. 1970 Feb;104(2):289-95.</citation>
    <PMID>4312871</PMID>
  </reference>
  <reference>
    <citation>Scott DA, Coulter WA, Biagioni PA, O'Neill HO, Lamey PJ. Detection of herpes simplex virus type 1 shedding in the oral cavity by polymerase chain reaction and enzyme-linked immunosorbent assay at the prodromal stage of recrudescent herpes labialis. J Oral Pathol Med. 1997 Aug;26(7):305-9.</citation>
    <PMID>9250929</PMID>
  </reference>
  <reference>
    <citation>Hobson A, Wald A, Wright N, Corey L. Evaluation of a quantitative competitive PCR assay for measuring herpes simplex virus DNA content in genital tract secretions. J Clin Microbiol. 1997 Mar;35(3):548-52.</citation>
    <PMID>9041386</PMID>
  </reference>
  <reference>
    <citation>Ryncarz AJ, Goddard J, Wald A, Huang ML, Roizman B, Corey L. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol. 1999 Jun;37(6):1941-7.</citation>
    <PMID>10325351</PMID>
  </reference>
  <reference>
    <citation>Kessler HH, Mühlbauer G, Rinner B, Stelzl E, Berger A, Dörr HW, Santner B, Marth E, Rabenau H. Detection of Herpes simplex virus DNA by real-time PCR. J Clin Microbiol. 2000 Jul;38(7):2638-42.</citation>
    <PMID>10878056</PMID>
  </reference>
  <reference>
    <citation>Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med. 1998 Jul 30;339(5):300-6.</citation>
    <PMID>9696640</PMID>
  </reference>
  <reference>
    <citation>Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM Jr, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M; Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004 Jan 1;350(1):11-20.</citation>
    <PMID>14702423</PMID>
  </reference>
  <reference>
    <citation>Crumpacker CS. Use of antiviral drugs to prevent herpesvirus transmission. N Engl J Med. 2004 Jan 1;350(1):67-8.</citation>
    <PMID>14702430</PMID>
  </reference>
  <reference>
    <citation>Gebhardt BM, Varnell ED, Kaufman HE. Acetylsalicylic acid reduces viral shedding induced by thermal stress. Curr Eye Res. 2004 Aug-Sep;29(2-3):119-25.</citation>
    <PMID>15512958</PMID>
  </reference>
  <reference>
    <citation>Anon. New indications. Valtrex. FDA Drug Approvals 38:572-573, 2003.</citation>
  </reference>
  <reference>
    <citation>Sheskin DJ. Handbook of Parametric and Nonparametric tatistical Procedures. 2nd Edition. Chapman &amp; Hall/CRC, Boca Raton, FL pp. 982,2000.</citation>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>December 21, 2007</last_update_submitted>
  <last_update_submitted_qc>December 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Herbert E Kaufman, MD, Boyd Professor Ophthalmology, Pharmacology</name_title>
    <organization>Louisiana State University Health Sciences Center in New Orleans</organization>
  </responsible_party>
  <keyword>HSV DNA</keyword>
  <keyword>volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

